Theratechnologies Inc Down 1.34% To $2.06 After Earnings Beat

Theratechnologies Inc (THTX) said before open Tuesday that it lost $0.03 per share in quarter three 2023.

On the revenue line, the company reported $20.9 million, missing estimates by $195 thousand.

In the same quarter a year ago, the company lost $0.32 per share on revenue of $20.8 million.

The stock is down 1.34% to $2.06 after the report.

The firm's lower revenue growth to earnings signals that the firm has been able to reduce costs and improve its profit margin overall.

The average recommendation from Wall Street analysts was a Buy which may get revised based on this new data.

Trading in the five days leading up to the report earned Theratechnologies Inc a Bearish Sentiment Rank from InvestorsObserver.

Theratechnologies Inc has performed a little above average during the past few months. Before the report, Theratechnologies Inc received a Long-Term Technical Rank by InvestorsObserver of 52, putting it in the top half of stocks. The firm was recently trading at a 52-week low of $0.9 on September 1, 2023 and set a 52-week high on October 3, 2022 at $11.06.

Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States.